A plasma-based multimetabolite biomarker for early detection of pancreatic cancer

Affiliations

¹ Biomarkers and Personalized Approach to Cancer (BIOPAC) Group, Ramón y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain. Electronic address: julie.earl@live.co.uk.

Comment

Julie Earl. Lancet Gastroenterol Hepatol. 2025 Jul.

. 2025 Jul;10(7):607-609.

doi: 10.1016/S2468-1253(25)00089-5. Epub 2025 May 16.

¹ Biomarkers and Personalized Approach to Cancer (BIOPAC) Group, Ramón y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain. Electronic address: julie.earl@live.co.uk.

No abstract available

Conflict of interest statement

I declare no competing interests.

Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study.
Mahajan UM, Oehrle B, Goni E, Strobel O, Kaiser J, Grützmann R, Werner J, Friess H, Gress TM, Seufferlein TW, Uhl W, Will U, Neoptolemos JP, Wittel UA, Vornhülz M, Sirtl S, Beyer G, Regel I, Boeck S, Heinemann V, Frost F, Steveling A, Völzke H, Petersmann A, Nauck M, Weber E, Kamlage B, Lerch MM, Mayerle J; METAPAC trial investigators. Mahajan UM, et al. Lancet Gastroenterol Hepatol. 2025 Jul;10(7):634-647. doi: 10.1016/S2468-1253(25)00056-1. Epub 2025 May 16. Lancet Gastroenterol Hepatol. 2025. PMID: 40388948 Clinical Trial.